Daiichi launches drug development consortium

Daiichi Sankyo Company has launched the Immune-mediated Inflammatory Diseases Consortium for Drug Development to research and discover drugs for intractable immune-mediated inflammatory diseases.

The consortium has been launched in collaboration with Keio University; Kochi University; the National Institutes of Biomedical Innovation, Health and Nutrition; Ono Pharmaceutical Co., and Mitsubishi Tanabe Pharma Corporation.

With the aim of curing intractable immune-mediated inflammatory diseases, reverse translational research for drug discovery research is being conducted worldwide using data on clinical samples analysed with the latest technologies.

However, as the number of clinical samples from patients with intractable immune-mediated inflammatory diseases is limited, and the increasing costs of drug discovery are burdensome, Daiichi has established this organisation to efficiently discover drugs through collaboration among multiple academia and industry members.

In the consortium, the Department of Rheumatology and Department of Gastroenterology and Hepatology, Keio University Hospital, and the Centre for Intractable Immune Disease, Kochi Medical School, Kochi University will collect samples and detailed clinical information before and after treatment as an inception cohort from the patients with multiple intractable immune-mediated inflammatory diseases.

These samples from the patients will be examined at the National Institutes of Biomedical Innovation, Health and Nutrition through detailed and comprehensive analysis, including transcriptome analysis.

A high-quality database, consisting of various types of data accumulated in the consortium, will be shared among the participating academia members and pharmaceutical companies.

While each pharmaceutical company conducts original drug discovery research for intractable immune-mediated inflammatory diseases utilizing this database, each academia member will utilize the study outcomes for further basic research and applied research.

The consortium will thus function based on this unprecedented concept of industry-academia collaboration.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Brilinta approved in US to reduce the risk of first heart attack or stroke

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with...

GSK to manufacture 1bn doses of pandemic vaccine

GlaxoSmithKline (GSK) is aiming to manufacture one billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted...

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Related news

Emergent joins partnership for COVID-19 vaccine development & manufacturing

Emergent BioSolutions has been issued a task order under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA) to deploy its...

Brilinta approved in US to reduce the risk of first heart attack or stroke

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with...

GSK to manufacture 1bn doses of pandemic vaccine

GlaxoSmithKline (GSK) is aiming to manufacture one billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted...

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...